CD11c (Dendritic Cell Marker) Antibody - Without BSA and Azide
Mouse Monoclonal Antibody [Clone HC1/1 ]
|Application ||IF, FC|
|Other Accession||3687, 248472|
|Isotype||Mouse / IgG1, kappa|
|Other Names||Integrin alpha-X, CD11 antigen-like family member C, Leu M5, Leukocyte adhesion glycoprotein p150, 95 alpha chain, Leukocyte adhesion receptor p150, 95, CD11c, ITGAX, CD11C|
|Format||200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.|
|Storage||Store at 2 to 8°C.Antibody is stable for 24 months.|
|Precautions||CD11c (Dendritic Cell Marker) Antibody - Without BSA and Azide is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Integrin alpha-X/beta-2 is a receptor for fibrinogen. It recognizes the sequence G-P-R in fibrinogen. It mediates cell-cell interaction during inflammatory responses. It is especially important in monocyte adhesion and chemotaxis.|
|Cellular Location||Membrane; Single-pass type I membrane protein|
|Tissue Location||Predominantly expressed in monocytes and granulocytes|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
CD11c, also known as Integrin, alpha X (complement component 3 receptor 4 subunit) (ITGAX), is a type I transmembrane protein found at high levels on most human dendritic cells, but also on monocytes, macrophages, neutrophils, and some B cells that induces cellular activation and helps trigger neutrophil respiratory burst; expressed in hairy cell leukemias, acute non-lymphocytic leukemias, and some B-cell chronic lymphocytic leukemias.
Nicolaou, F., et al. 2003. CD11c gene expression in hairy cell leukemia is dependent upon activation of the proto-oncogenes Ras and JunD. Blood 101: 4033-4041. | Edwards, A.D., et al. 2003. Relationships among murine CD11c (high) dendritic cell subsets as revealed by baseline gene expression patterns. J. Immunol. 171: 47-60
If you have any additional inquiries please email technical services at firstname.lastname@example.org.